1. Mulberroside has nephroprotective, hypoglycemic, and antidiabetic effects.
2. Mulberroside A is a glycosylated stilbene of oxyresveratrol; thus, the deglycosylation of Mulberroside A resulted in enhanced inhibition of melanogenesis.
3. Mulberroside A has anti-inflammatory antiapoptotic effects. by decreasing the expressions of tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-6 and inhibiting the activation of NALP3, caspase-1, and nuclear factor-κB and the phosphorylation of extracellular signal-regulated protein kinases, the c-Jun N-terminal kinase, and p38.
1. Nuciferine is an important drug candidate for the treatment of obesity-related diseases, through ameliorating HFD-induced dyslipidemia as well as liver steatosis and injury.
2. Nuciferine may be potential for the prevention and treatment of hyperuricemia with kidney inflammation.
3. Nuciferine has a vasorelaxant effect via both endothelium-dependent and -independent mechanisms. These results suggest that Nuciferine may have a therapeutic effect on vascular diseases associated with aberrant vasoconstriction.